FY2023 EPS Estimates for Theratechnologies Inc. Decreased by Leede Jones Gab (NASDAQ:THTX)

Posted by on Jul 17th, 2023

Theratechnologies Inc. (NASDAQ:THTX – Free Report) – Stock analysts at Leede Jones Gab lowered their FY2023 earnings per share estimates for shares of Theratechnologies in a research note issued to investors on Thursday, July 13th. Leede Jones Gab analyst D. Loe now forecasts that the company will post earnings per share of ($0.27) for the year, down from their prior forecast of ($0.24). The consensus estimate for Theratechnologies’ current full-year earnings is ($0.22) per share. Leede Jones Gab also issued estimates for Theratechnologies’ FY2024 earnings at ($0.20) EPS, FY2025 earnings at ($0.07) EPS and FY2027 earnings at $0.20 EPS.

Theratechnologies (NASDAQ:THTX – Get Free Report) last issued its quarterly earnings results on Wednesday, July 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The firm had revenue of $17.55 million during the quarter.

Separately, National Bank Financial decreased their price target on Theratechnologies from C$3.25 to C$2.25 in a research note on Thursday, April 13th.

Theratechnologies Stock Performance

Shares of THTX opened at $0.86 on Monday. Theratechnologies has a 52-week low of $0.70 and a 52-week high of $2.77. The business’s fifty day moving average is $0.92 and its 200-day moving average is $0.92. The firm has a market cap of $83.19 million, a price-to-earnings ratio of -2.26 and a beta of 1.19.

Institutional Investors Weigh In On Theratechnologies

Several hedge funds have recently modified their holdings of the company. Virtu Financial LLC boosted its holdings in shares of Theratechnologies by 48.8% during the 2nd quarter. Virtu Financial LLC now owns 22,062 shares of the company’s stock valued at $50,000 after acquiring an additional 7,237 shares in the last quarter. HighTower Advisors LLC acquired a new stake in shares of Theratechnologies during the 1st quarter valued at $34,000. Range Financial Group LLC acquired a new stake in shares of Theratechnologies during the 1st quarter valued at $35,000. Atria Wealth Solutions Inc. acquired a new stake in shares of Theratechnologies during the 2nd quarter valued at $33,000. Finally, Advisor Group Holdings Inc. boosted its holdings in shares of Theratechnologies by 13.0% during the 4th quarter. Advisor Group Holdings Inc. now owns 434,155 shares of the company’s stock valued at $383,000 after acquiring an additional 49,950 shares in the last quarter. Institutional investors and hedge funds own 25.41% of the company’s stock.

About Theratechnologies

(Get Free Report)

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients.

Read More

Earnings History and Estimates for Theratechnologies (NASDAQ:THTX)

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.